Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients With Select, Relapsed or Refractory Hematologic Malignancies.

Next Previous
Search
Trial Profile

A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients With Select, Relapsed or Refractory Hematologic Malignancies.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Acute myeloid leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 08 Dec 2015 Results of post-hoc analysis (n=494) of this and other three trial (see profile 59751, 54699 and 214177) were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2015 Results of a pooled post hoc analysis presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 08 Dec 2015 Post hoc results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top